Page 293 - Haematologica March 2020

Long-term eradication of ENKL by rejuvenated CTL
References
1. Tse E, Kwong YL. How I treat NK/T-cell lymphomas. Blood. 2013;121(25):4997- 5005.
2. Oshimi K. Progress in understanding and managing natural killer-cell malignancies. Br J Haematol. 2007;139(4):532-544.
3. Egashira M, Kawamata N, Sugimoto K, Kaneko T, Oshimi K. P-glycoprotein expres- sion on normal and abnormally expanded natural killer cells and inhibition of P-glyco- protein function by cyclosporin A and its analogue, PSC833. Blood. 1999;93(2):599- 606.
4. Ando M, Sugimoto K, Kitoh T, et al. Selective apoptosis of natural killer-cell tumours by l-asparaginase. Br J Haematol. 2005;130(6):860-868.
5. Yamaguchi M, Kwong YL, Kim WS, et al. Phase II study of SMILE chemotherapy for newly diagnosed stage IV, relapsed, or refractory extranodal natural killer (NK)/T- cell lymphoma, nasal type: the NK-Cell Tumor Study Group study. J Clin Oncol. 2011;29(33):4410-4416.
6. Kwong YL, Kim WS, Lim ST, et al. SMILE for natural killer/T-cell lymphoma: analysis of safety and efficacy from the Asia Lymphoma Study Group. Blood. 2012;120(15):2973-2980.
7. RosenbergSA,PackardBS,AebersoldPM,et al. Use of tumor-infiltrating lymphocytes and interleukin-2 in the immunotherapy of patients with metastatic melanoma. A pre- liminary report. N Engl J Med. 1988;319(25):1676-1680.
8. Dudley ME, Wunderlich JR, Robbins PF, et al. Cancer regression and autoimmunity in patients after clonal repopulation with anti- tumor lymphocytes. Science. 2002;298 (5594):850-854.
9. Dudley ME, Wunderlich JR, Yang JC, et al. Adoptive cell transfer therapy following non-myeloablative but lymphodepleting chemotherapy for the treatment of patients with refractory metastatic melanoma. J Clin Oncol. 2005;23(10):2346-2357.
10. Restifo NP, Dudley ME, Rosenberg SA. Adoptive immunotherapy for cancer: har- nessing the T cell response. Nat Rev Immunol. 2012;12(4):269-281.
11. Rooney CM, Smith CA, Ng CY, et al.
Infusion of cytotoxic T cells for the preven- tion and treatment of Epstein-Barr virus- induced lymphoma in allogeneic transplant recipients. Blood. 1998;92(5):1549-1555.
12. Gottschalk S, Edwards OL, Sili U, et al. Generating CTLs against the subdominant Epstein-Barr virus LMP1 antigen for the adoptive immunotherapy of EBV-associated malignancies. Blood. 2003;101(5):1905- 1912.
13. Heslop HE, Slobod KS, Pule MA, et al. Long- term outcome of EBV-specific T-cell infu- sions to prevent or treat EBV-related lym- phoproliferative disease in transplant recipi- ents. Blood. 2010;115(5):925-935.
14. Bollard CM, Rooney CM, Heslop HE. T-cell therapy in the treatment of post-transplant lymphoproliferative disease. Nat Rev Clin Oncol. 2012;9(9):510-519.
15. Bollard CM, Gottschalk S, Leen AM, et al. Complete responses of relapsed lymphoma following genetic modification of tumor- antigen presenting cells and T-lymphocyte transfer. Blood. 2007;110(8):2838-2845.
16. Bollard CM, Gottschalk S, Torrano V, et al. Sustained complete responses in patients with lymphoma receiving autologous cyto- toxic T lymphocytes targeting Epstein-Barr virus latent membrane proteins. J Clin Oncol. 2014;32(8):798-808.
17. Wherry EJ. T cell exhaustion. Nat Immunol. 2011;12(6):492-499.
18. Nishimura T, Kaneko S, Kawana-Tachikawa A, et al. Generation of rejuvenated antigen- specific T cells by reprogramming to pluripotency and redifferentiation. Cell Stem Cell. 2013;12(1):114-126.
19. Ando M, Nishimura T, Yamazaki S, et al. A safeguard system for induced pluripotent stem cell-derived rejuvenated T cell therapy. Stem Cell Reports. 2015;5(4):597-608.
20. Ando M, Nakauchi H. 'Off-the-shelf' immunotherapy with iPSC-derived rejuve- nated cytotoxic T lymphocytes. Exp Hematol. 2017;47:2-12.
21. Okazaki T, Maeda A, Nishimura H, Kurosaki T, Honjo T. PD-1 immunoreceptor inhibits B cell receptor-mediated signaling by recruiting src homology 2-domain-con- taining tyrosine phosphatase 2 to phospho- tyrosine. Proc Natl Acad Sci U S A. 2001;98(24):13866-13871.
22. Okazaki T, Chikuma S, Iwai Y, Fagarasan S, Honjo T. A rheostat for immune responses:
the unique properties of PD-1 and their advantages for clinical application. Nat Immunol. 2013;14(12):1212-1218.
23. Ansell SM, Lesokhin AM, Borrello I, et al. PD-1 blockade with nivolumab in relapsed or refractory Hodgkin's lymphoma. N Engl J Med. 2015;372(4):311-319.
24. Yamamoto R, Nishikori M, Kitawaki T, et al. PD-1-PD-1 ligand interaction contributes to immunosuppressive microenvironment of Hodgkin lymphoma. Blood. 2008;111(6): 3220-3224.
25. Green MR, Rodig S, Juszczynski P, et al. Constitutive AP-1 activity and EBV infection induce PD-L1 in Hodgkin lymphomas and posttransplant lymphoproliferative disor- ders: implications for targeted therapy. Clin Cancer Res. 2012;18(6):1611-1618.
26. Kiyasu J, Miyoshi H, Hirata A, et al. Expression of programmed cell death ligand 1 is associated with poor overall survival in patients with diffuse large B-cell lymphoma. Blood. 2015;126(19):2193-2201.
27. Kwong YL, Chan TSY, Tan D, et al. PD1 blockade with pembrolizumab is highly effective in relapsed or refractory NK/T-cell lymphoma failing l-asparaginase. Blood. 2017;129(17):2437-2442.
28. Nagata H, Konno A, Kimura N, et al. Characterization of novel natural killer (NK)-cell and gammadelta T-cell lines estab- lished from primary lesions of nasal T/NK- cell lymphomas associated with the Epstein- Barr virus. Blood. 2001;97(3):708-713.
29. Gottschalk S, Ng CY, Perez M, et al. An Epstein-Barr virus deletion mutant associat- ed with fatal lymphoproliferative disease unresponsive to therapy with virus-specific CTLs. Blood. 2001;97(4):835-843.
30. Themeli M, Kloss CC, Ciriello G, et al. Generation of tumor-targeted human T lym- phocytes from induced pluripotent stem cells for cancer therapy. Nat Biotechnol. 2013;31(10):928-933.
31. Heczey A, Louis CU, Savoldo B, et al. CAR T Cells Administered in Combination with Lymphodepletion and PD-1 Inhibition to Patients with Neuroblastoma. Mol Ther. 2017;25(9):2214-2224.
32. Naidoo J, Page DB, Li BT, et al. Toxicities of the anti-PD-1 and anti-PD-L1 immune checkpoint antibodies. Ann Oncol. 2016; 27(7):1362.
haematologica | 2020; 105(3)
807